{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:16:25Z","timestamp":1769170585211,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CV185-509"],"award-info":[{"award-number":["CV185-509"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Prim. Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Many patients taking direct-acting oral anticoagulants (DOACs) also consume over-the-counter (OTC) products (dietary supplements and OTC medications), yet many lack knowledge of potential interactions that may increase or decrease DOAC efficacy and may not seek information about OTC products. The objective of this study was to describe patient attitudes and beliefs that inhibited information seeking about potential apixaban-OTC product interactions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Participants included English-, Spanish-, Mandarin-, and Cantonese-speaking adults from two large academic medical centers who reported taking apixaban (a frequently prescribed DOAC) in the past month. Thematic analysis was performed on semi-structured interviews.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Sixty patients aged 24\u201393 years (mean\u2009=\u200965.3; SD\u2009=\u200915.6) were interviewed; 55% were women. Participants took a total of 236 OTC products. Those with potential interactions with apixaban warranting consideration for therapy modification included: ibuprofen (<jats:italic>n<\/jats:italic>\u2009=\u200914; 5.9%), aspirin (<jats:italic>n<\/jats:italic>\u2009=\u20098; 3.4%), and naproxen (<jats:italic>n<\/jats:italic>\u2009=\u20093; 1.3%). Interviews revealed 5 major themes related to a lack of information-seeking about OTC products: (1) patients lack awareness of the potential for interactions; (2) patients believe that OTC products are safe and\/or regulated (largely because they were familiar with the products, had previously taken them, or assumed that dietary supplements were regulated by the Food and Drug Administration); (3) patients believe that providers are responsible for alerting patients about potential interactions (as patients assumed that providers were aware of their OTC product use); (4) patients had prior knowledge of and\/or used OTC products infrequently; and (5) obtaining information can be inconvenient. Inquiries regarding preferred information sources revealed 59 (98.3%) patients most frequently sought or would seek information from physicians and 34 (56.7%) from the internet.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Patients taking apixaban raised reasons for not seeking information about potential OTC product interactions that included poor awareness, perceptions regarding the safety of OTC products, and beliefs in provider responsibility for informing them about interactions. Greater patient education is needed regarding the potential for OTC product-DOAC interactions and the regulation of OTC products, particularly dietary supplements.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12875-025-02740-1","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:08:48Z","timestamp":1740146928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Why patients fail to seek information on OTC product interactions with a direct-acting oral anticoagulant: perspectives on information-seeking"],"prefix":"10.1186","volume":"26","author":[{"given":"Marley P.D.","family":"Magee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice B.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruey-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derjung M.","family":"Tarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"6","key":"2740_CR1","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Baumann Kreuziger L, et al. Executive Summary: antithrombotic therapy for VTE Disease: second update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):2247\u201359. https:\/\/doi.org\/10.1016\/j.chest.2021.07.056.","journal-title":"Chest"},{"key":"2740_CR2","doi-asserted-by":"publisher","first-page":"m1565","DOI":"10.1136\/bmj.m1565","volume":"369","author":"T McCormack","year":"2020","unstructured":"McCormack T, Harrisingh MC, Horner D, Bewley S. Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing. BMJ. 2020;369:m1565. https:\/\/doi.org\/10.1136\/bmj.m1565.","journal-title":"BMJ"},{"issue":"1","key":"2740_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS Guideline for the management of patients with Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.011.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2740_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927\u201374. https:\/\/doi.org\/10.1182\/bloodadvances.2020003442.","journal-title":"Blood Adv"},{"issue":"5","key":"2740_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/jco.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020;38(5):496\u2013520. https:\/\/doi.org\/10.1200\/jco.19.01461.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2740_CR6","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","volume":"20","author":"D Farge","year":"2019","unstructured":"Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(19)30336-5.","journal-title":"Lancet Oncol"},{"key":"2740_CR7","doi-asserted-by":"publisher","unstructured":"da Costa LS, Alsultan MM, Hincapie AL, Guo JJ. Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020. J Thromb Thrombolysis Published Online November. 2022;19. https:\/\/doi.org\/10.1007\/s11239-022-02727-0.","DOI":"10.1007\/s11239-022-02727-0"},{"issue":"22","key":"2740_CR8","doi-asserted-by":"publisher","first-page":"e026723","DOI":"10.1161\/JAHA.122.026723","volume":"11","author":"AM Navar","year":"2022","unstructured":"Navar AM, Kolkailah AA, Overton R, et al. Trends in oral anticoagulant use among 436 864 patients with Atrial Fibrillation in Community Practice, 2011 to 2020. J Am Heart Assoc. 2022;11(22):e026723. https:\/\/doi.org\/10.1161\/JAHA.122.026723.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"2740_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3949\/ccjm.82a.14052","volume":"82","author":"B Roca","year":"2015","unstructured":"Roca B, Roca M. The new oral anticoagulants: reasonable alternatives to warfarin. Cleve Clin J Med. 2015;82(12):847\u201354. https:\/\/doi.org\/10.3949\/ccjm.82a.14052.","journal-title":"Cleve Clin J Med"},{"issue":"11","key":"2740_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/01.JAA.0000471615.92278.1c","volume":"28","author":"A Holden","year":"2015","unstructured":"Holden A, Azimi N, Forest CP. New oral anticoagulants for patients with nonvalvular atrial fibrillation. JAAPA off J Am Acad Physician Assist. 2015;28(11):28\u201334. https:\/\/doi.org\/10.1097\/01.JAA.0000471615.92278.1c.","journal-title":"JAAPA off J Am Acad Physician Assist"},{"key":"2740_CR11","doi-asserted-by":"publisher","first-page":"w14286","DOI":"10.4414\/smw.2016.14286","volume":"146","author":"P Fontana","year":"2016","unstructured":"Fontana P, Robert-Ebadi H, Bounameaux H, Boehlen F, Righini M. Direct oral anticoagulants: a guide for daily practice. Swiss Med Wkly. 2016;146:w14286. https:\/\/doi.org\/10.4414\/smw.2016.14286.","journal-title":"Swiss Med Wkly"},{"issue":"13","key":"2740_CR12","doi-asserted-by":"publisher","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Warden A. Direct oral anticoagulant use: a practical guide to Common Clinical challenges. J Am Heart Assoc. 2020;9(13):e017559. https:\/\/doi.org\/10.1161\/JAHA.120.017559.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2740_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11239-016-1446-0","volume":"43","author":"A Zirlik","year":"2017","unstructured":"Zirlik A, Bode C. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis. 2017;43(3):365\u201379. https:\/\/doi.org\/10.1007\/s11239-016-1446-0.","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2740_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1055\/s-0035-1544231","volume":"41","author":"N Riva","year":"2015","unstructured":"Riva N, Ageno W. Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost. 2015;41(2):178\u201387. https:\/\/doi.org\/10.1055\/s-0035-1544231.","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"2740_CR15","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/pharmaceutics14061120","volume":"14","author":"N Ferri","year":"2022","unstructured":"Ferri N, Colombo E, Tenconi M, Baldessin L, Corsini A. Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics. 2022;14(6):1120. https:\/\/doi.org\/10.3390\/pharmaceutics14061120.","journal-title":"Pharmaceutics"},{"issue":"16","key":"2740_CR16","doi-asserted-by":"publisher","first-page":"8531","DOI":"10.3390\/ijms22168531","volume":"22","author":"G Grze\u015bk","year":"2021","unstructured":"Grze\u015bk G, Rogowicz D, Wo\u0142owiec \u0141, et al. The clinical significance of drug\u2013food interactions of direct oral anticoagulants. Int J Mol Sci. 2021;22(16):8531. https:\/\/doi.org\/10.3390\/ijms22168531.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2740_CR17","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jacc.2019.12.068","volume":"75","author":"BS Wiggins","year":"2020","unstructured":"Wiggins BS, Dixon DL, Neyens RR, Page RL, Gluckman TJ. Select drug-drug interactions with direct oral anticoagulants: JACC Review topic of the Week. J Am Coll Cardiol. 2020;75(11):1341\u201350. https:\/\/doi.org\/10.1016\/j.jacc.2019.12.068.","journal-title":"J Am Coll Cardiol"},{"key":"2740_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.thromres.2020.07.054","volume":"195","author":"JY Lee","year":"2020","unstructured":"Lee JY, Oh IY, Lee JH, et al. The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants. Thromb Res. 2020;195:243\u20139. https:\/\/doi.org\/10.1016\/j.thromres.2020.07.054.","journal-title":"Thromb Res"},{"issue":"8","key":"2740_CR19","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1007\/s11606-020-05904-0","volume":"35","author":"M Colacci","year":"2020","unstructured":"Colacci M, Tseng EK, Sacks CA, Fralick M. Oral anticoagulant utilization in the United States and United Kingdom. J Gen Intern Med. 2020;35(8):2505\u20137. https:\/\/doi.org\/10.1007\/s11606-020-05904-0.","journal-title":"J Gen Intern Med"},{"key":"2740_CR20","unstructured":"Office of Dietary Supplements - Dietary Supplement Health and Education Act of 1994. Accessed October 8. 2024. https:\/\/ods.od.nih.gov\/About\/DSHEA_Wording.aspx"},{"key":"2740_CR21","doi-asserted-by":"publisher","unstructured":"Tarn DM, Barrientos M, Wang AY, Ramaprasad A, Fang MC, Schwartz JB. Prevalence and Knowledge of Potential Interactions Between Over-the-Counter Products and Apixaban. J Am Geriatr Soc. Published online October 28, 2019. https:\/\/doi.org\/10.1111\/jgs.16193","DOI":"10.1111\/jgs.16193"},{"key":"2740_CR22","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.2147\/ppa.S173651","volume":"12","author":"MK Kusch","year":"2018","unstructured":"Kusch MK, Haefeli WE, Seidling HM. How to meet patients\u2019 individual needs for drug information - a scoping review. Patient Prefer Adherence. 2018;12:2339\u201355. https:\/\/doi.org\/10.2147\/ppa.S173651.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"2740_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1331\/JAPhA.2013.12038","volume":"53","author":"A Mutebi","year":"2013","unstructured":"Mutebi A, Warholak TL, Hines LE, Plummer R, Malone DC. Assessing patients\u2019 information needs regarding drug-drug interactions. J Am Pharm Assoc. 2013;53(1):39\u201345. https:\/\/doi.org\/10.1331\/JAPhA.2013.12038.","journal-title":"J Am Pharm Assoc"},{"issue":"2","key":"2740_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1369-7625.2006.00381.x","volume":"9","author":"M Koo","year":"2006","unstructured":"Koo M, Krass I, Aslani P. Enhancing patient education about medicines: factors influencing reading and seeking of written medicine information. Health Expect Int J Public Particip Health Care Health Policy. 2006;9(2):174\u201387. https:\/\/doi.org\/10.1111\/j.1369-7625.2006.00381.x.","journal-title":"Health Expect Int J Public Particip Health Care Health Policy"},{"issue":"3","key":"2740_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1369-7625.2005.00339.x","volume":"8","author":"DR Longo","year":"2005","unstructured":"Longo DR. Understanding health information, communication, and information seeking of patients and consumers: a comprehensive and integrated model. Health Expect Int J Public Particip Health Care Health Policy. 2005;8(3):189\u201394. https:\/\/doi.org\/10.1111\/j.1369-7625.2005.00339.x.","journal-title":"Health Expect Int J Public Particip Health Care Health Policy"},{"issue":"4","key":"2740_CR26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1370\/afm.1115","volume":"8","author":"DR Longo","year":"2010","unstructured":"Longo DR, Schubert SL, Wright BA, LeMaster J, Williams CD, Clore JN. Health Information seeking, receipt, and use in diabetes self-management. Ann Fam Med. 2010;8(4):334\u201340. https:\/\/doi.org\/10.1370\/afm.1115.","journal-title":"Ann Fam Med"},{"issue":"1","key":"2740_CR27","doi-asserted-by":"publisher","first-page":"160940691773384","DOI":"10.1177\/1609406917733847","volume":"16","author":"LS Nowell","year":"2017","unstructured":"Nowell LS, Norris JM, White DE, Moules NJ. Thematic analysis: striving to meet the trustworthiness Criteria. Int J Qual Methods. 2017;16(1):1609406917733847. https:\/\/doi.org\/10.1177\/1609406917733847.","journal-title":"Int J Qual Methods"},{"issue":"2","key":"2740_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"key":"2740_CR29","unstructured":"Maguire M, Delahunt B. Doing a thematic analysis: A practical, step-by-step guide for learning and teaching scholars. Irel J High Educ. 2017;9(3). Accessed October 3, 2024. https:\/\/ojs.aishe.org\/index.php\/aishe-j\/article\/view\/335"},{"issue":"8","key":"2740_CR30","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/jcph.2046","volume":"62","author":"CM White","year":"2022","unstructured":"White CM, Continued Risk of Dietary Supplements Adulterated With Approved and Unapproved Drugs. Assessment of the US Food and Drug Administration\u2019s tainted supplements database 2007 through 2021. J Clin Pharmacol. 2022;62(8):928\u201334. https:\/\/doi.org\/10.1002\/jcph.2046.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"2740_CR31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1037\/0278-6133.26.4.513","volume":"26","author":"T Dodge","year":"2007","unstructured":"Dodge T, Kaufman A. What makes consumers think dietary supplements are safe and effective? The role of disclaimers and FDA approval. Health Psychol off J Div Health Psychol Am Psychol Assoc. 2007;26(4):513\u20137. https:\/\/doi.org\/10.1037\/0278-6133.26.4.513.","journal-title":"Health Psychol off J Div Health Psychol Am Psychol Assoc"},{"issue":"1","key":"2740_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/CIRCULATIONAHA.119.041296","volume":"141","author":"F Dalgaard","year":"2020","unstructured":"Dalgaard F, Mulder H, Wojdyla DM, et al. Patients with Atrial Fibrillation taking nonsteroidal anti-inflammatory drugs and oral anticoagulants in the ARISTOTLE Trial. Circulation. 2020;141(1):10\u201320. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.041296.","journal-title":"Circulation"},{"issue":"9\u201310","key":"2740_CR33","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1055\/a-0605-3786","volume":"84","author":"A Hudson","year":"2018","unstructured":"Hudson A, Lopez E, Almalki AJ, Roe AL, Calder\u00f3n AI. A review of the toxicity of compounds found in Herbal Dietary supplements. Planta Med. 2018;84(9\u201310):613\u201326. https:\/\/doi.org\/10.1055\/a-0605-3786.","journal-title":"Planta Med"},{"issue":"6","key":"2740_CR34","doi-asserted-by":"publisher","first-page":"e0218398","DOI":"10.1371\/journal.pone.0218398","volume":"14","author":"MS Karbownik","year":"2019","unstructured":"Karbownik MS, Paul E, Nowicka M, et al. Knowledge about dietary supplements and trust in advertising them: Development and validation of the questionnaires and preliminary results of the association between the constructs. PLoS ONE. 2019;14(6):e0218398. https:\/\/doi.org\/10.1371\/journal.pone.0218398.","journal-title":"PLoS ONE"},{"issue":"7","key":"2740_CR35","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.pec.2015.03.020","volume":"98","author":"DM Tarn","year":"2015","unstructured":"Tarn DM, Karlamangla A, Coulter ID, et al. A cross-sectional study of provider and patient characteristics associated with outpatient disclosures of dietary supplement use. Patient Educ Couns. 2015;98(7):830\u20136. https:\/\/doi.org\/10.1016\/j.pec.2015.03.020.","journal-title":"Patient Educ Couns"},{"issue":"3","key":"2740_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.pec.2013.01.021","volume":"91","author":"DM Tarn","year":"2013","unstructured":"Tarn DM, Paterniti DA, Good JS, et al. Physician-patient communication about dietary supplements. Patient Educ Couns. 2013;91(3):287\u201394. https:\/\/doi.org\/10.1016\/j.pec.2013.01.021.","journal-title":"Patient Educ Couns"},{"issue":"7","key":"2740_CR37","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/jgs.12915","volume":"62","author":"DJ Jang","year":"2014","unstructured":"Jang DJ, Tarn DM. Infrequent older adult-primary care provider discussion and documentation of dietary supplements. J Am Geriatr Soc. 2014;62(7):1386\u20138. https:\/\/doi.org\/10.1111\/jgs.12915.","journal-title":"J Am Geriatr Soc"}],"container-title":["BMC Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-02740-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12875-025-02740-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-02740-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:09:05Z","timestamp":1740146945000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcfampract.biomedcentral.com\/articles\/10.1186\/s12875-025-02740-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2740"],"URL":"https:\/\/doi.org\/10.1186\/s12875-025-02740-1","relation":{},"ISSN":["2731-4553"],"issn-type":[{"value":"2731-4553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"22 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study procedures were approved by the UCLA Institutional Review Board (IRB #16\u2013000888) in accordance with the Declaration of Helsinki, with UCSF relying on UCLA\u2019s IRB through the UC IRB Reliance Registry. Verbal informed consent was obtained from all participants to take part in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JBS and DMT have been funded by investigator-initiated research awards from Bristol-Myers Squibb and Pfizer, as part of the American Thrombosis Investigator Initiated Research Program (ARISTA-USA). MM, AM, and RL have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}